Actively Recruiting
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Led by Niek Wijnen · Updated on 2026-03-30
15
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
N
Niek Wijnen
Lead Sponsor
P
PAION Deutschland GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization. The main questions it aims to answer are: * Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver? * Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do? * First visit (work-up): Participants will have the standard preparation for radioembolization. A small test dose of radioactive tracer technetium 99mTc macroaggregated albumin (99mTc-MAA) will be injected into the liver through an artery. On the same day, a single-photon emission computed tomography (SPECT)/CT scan will be performed to see how the tracer distributes in the liver and if there are depositions outside the liver. If everything looks good, the participant will return for treatment in 2-3 weeks. * Second visit (treatment): Participants will receive the actual radioembolization treatment. At each injection site in the liver, first angiotensin II is administered, immediately followed by the injection of the radioactive beads (90Y microspheres). If the treatment requires injections in multiple locations, the participant will receive angiotensin II at each spot. * After treatment: Participants will receive a Positron Emission Tomography (PET)/CT scan so the research team can see where the radioactive beads went. This will be compared to the distribution of the radioactive tracer (99mTc-MAA) from the first SPECT/CT scan (performed without angiotensin II) to measure how much angiotensin II helped target the tumor. All monitoring (including blood pressure, heart rate, oxygen saturation, and breathing rate) takes place during the procedure as part of routine care, and there are no extra hospital visits beyond what is normally required for radioembolization.
CONDITIONS
Official Title
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with primary or metastatic liver tumors (any histological type).
- A clinical indication for radioembolization.
- Liver tumors with a diameter 65 2 cm.
- Age 65 18 years.
- Competent and able to provide own informed consent (no legally designated representative).
- Written informed consent.
You will not qualify if you...
- Any serious comorbidity preventing safe administration of angiotensin II, including uncontrolled hypertension.
- Treatment with three or more antihypertensive drugs.
- Arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months.
- Current use of angiotensin-converting enzyme (ACE) inhibitors.
- Current use of angiotensin II receptor blockers (ARBs).
- Known hypercoagulable state (thrombophilia).
- History of severe peripheral vascular disease.
- Known hypersensitivity to angiotensin II or excipients in Giapreza (mannitol, sodium hydroxide, hydrochloric acid).
- Any serious or chronic liver disease preventing safe radioembolization.
- Uncorrectable extrahepatic deposition of scout dose activity (except in falciform ligament, portal lymph nodes, gallbladder).
- Pregnancy or breastfeeding.
- Body weight over 150 kg.
- Known severe allergy to intravenous contrast fluids.
- Participation in another investigational study that may affect study endpoints.
- Any other significant comorbidity or medical condition that may compromise radioembolization safety.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands, 3584 CX
Actively Recruiting
Research Team
N
Niek Wijnen, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here